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306 The Journal of Thoracic and Cardbjective: Our objective was to evaluate the outcomes of radiofrequency ablation
or nonsurgical candidates with clinical stage I non–small cell lung cancer.
ethods: This study was carried out on 20 nonsurgical candidates (11 men and 9
omen; mean age, 75.6 years) with clinical stage I (IA, n  14; IB, n  6)
on–small cell lung cancer. All patients were deemed nonsurgical candidates
ecause of poor pulmonary function (n  7), poor cardiac function (n  3), poor
erformance status (n  4), or refusal to undergo surgery (n  6). The mean
ong-axis tumor diameter was 2.4 cm. Twenty patients underwent 23 percutaneous
blation sessions, including 3 repeat sessions for the treatment of local progression.
he outcomes of radiofrequency ablation were retrospectively evaluated.
esults: Procedural complications included pneumothorax (n  13 [57%]) and
leural effusion (n  4 [17%]). One case of pneumothorax required chest tube
lacement. The median follow-up period was 21.8 months. Local progression was
bserved in 7 (35%) patients a median of 9.0 months after the first session. The local
ontrol rates were 72% at 1 year, 63% at 2 years, and 63% at 3 years. The mean
urvival time was 42 months. The overall survivals and cancer-specific survivals
ere 90% and 100% at 1 year, 84% and 93% at 2 years, and 74% and 83% at
years, respectively.
onclusions: Treating clinical stage I non–small cell lung cancer with one or more
adiofrequency ablation sessions provided promising outcomes in terms of survival,
lthough the rate of local progression was relatively high. A prospective study with
larger population and longer follow-up is warranted.
rimary lung cancer is the most common malignant disease and the leading
cause of death from cancer worldwide. Surgical resection is the first-line
treatment and the best option for treating early-stage non–small cell lung
ancer (NSCLC). Although some surgeons believe that limited resection is effective
n treating localized cancer, lobectomy is considered to be the gold standard of
urgery because a large randomized controlled trial demonstrated the superiority of
obectomy as compared with limited resection in terms of both patient survival and
ocoregional recurrence in T1 N0 NSCLC.1 Unfortunately, certain patients are
onsidered medically inoperable. Conventional external beam radiation therapy
XRT) has been traditionally administered to such patients; the outcomes, however,
re suboptimal. Thus, various alternative modalities, including radiofrequency ab-
ation (RFA), have been the focus of many studies.
RFA is a thermal therapy that results in coagulation necrosis. The procedure
nvolves placement of an electrode into the target followed by application of
adiofrequency energy. Initially, RFA was mainly used for treating hepatocellular
iovascular Surgery ● November 2007
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TSarcinoma. The favorable outcomes in the treatment of
epatocellular carcinoma have encouraged the application
f this technique to neoplasms in other organs, including the
ungs. Preliminary studies of RFA in treating lung tumors
ave shown promising results for initial local control.2,3 The
urpose of this study was to retrospectively evaluate the
utcomes of RFA when used to treat nonsurgical candidates
ith clinical stage I NSCLC.
atients and Methods
tudy Population
pproval from the institutional review board and informed con-
ents from the patients were obtained to perform RFA of lung
umors. From June 2001 to February 2006, we treated 209 patients
aving primary lung cancer (n  40) or metastatic lung neoplasms
rom various primary sites (n  169) with 329 percutaneous RFA
essions at our institution. Of the 40 patients with primary lung
ancer, 20 were excluded from the study: 18 had clinical stage II
ancer or higher and were treated with a combination of RFA and
Abbreviations and Acronyms
CT  computed tomography
NSCLC non–small cell lung cancer
PET  positron emission tomography
RFA  radiofrequency ablation
XRT  external beam radiation therapy
ABLE 1. Patient and tumor characteristics and follow-up
atient
o.
Age
(yr) Sex Pathology
Size
(cm) Stage
F
1 79 Male Adeno 1.5 IA
2 81 Male Squamous 2 IA
3 88 Female Squamous 2.8 IB
4 79 Male Squamous 3.7 IB
5 81 Male Squamous 6 IB
6 80 Female Adeno 1.6 IA
7 65 Female Squamous 2 IA
8 77 Male Squamous 1.6 IA
9 67 Male Squamous 2.1 IA
0 79 Male Adeno 3.2 IB
1 78 Female Adeno 2.5 IA
2 77 Female Adeno 1.3 IA
3 67 Male Adeno 3 IB
4 77 Female Adeno 3.4 IB
5 65 Female Adeno 1.5 IA
6 73 Male Adeno 1.6 IA
7 72 Male Adeno 1.7 IA
8 64 Male Adeno 1.8 IA
9 78 Female Adeno 1.4 IA
0 84 Female Adeno 2.3 IA
verage 75.6 2.4 22.2
The Journal of Thoracicystemic chemotherapy, and 2 had clinical stage I cancer but were
reated by a combination of RFA and XRT owing to a large tumor
ize. Clinical stage I NSCLC was diagnosed in the remaining 20
atients, and they were treated by RFA alone; these patients
ormed the basis of our study. For clinical staging, chest and
bdominal computed tomographic (CT) scans were performed in
ll patients. Further, brain magnetic resonance imaging and bone
cintiscan were performed in 6 patients and in 2 patients, respec-
ively. Because our institution was not equipped with positron
mission tomography (PET) facilitates, none of the patients un-
erwent PET scanning except for 3 patients who underwent it at
nother institution. None of the patients underwent mediastinos-
opy, endoscopic ultrasound-guided fine needle aspiration, or en-
oscopic bronchial ultrasonography for the examination of lymph
ode involvement. Thus, lymph node involvement was evaluated
n CT images, and lymph node metastasis was considered absent
ecause none of the lymph nodes was larger than 1.0 cm in
hort-axis diameter.
The characteristics of the 20 patients and the tumors are sum-
arized in Table 1. In brief, there were 11 men and 9 women
mean age, 75.6 years; range, 64–88 years). Of the 20 patients, 13
ad adenocarcinoma including 3 patients with lesions showing
ure ground-glass opacity and 7 had squamous cell carcinoma.
linical stage IA and IB cancers were diagnosed in 14 and 6
atients, respectively. The mean long-axis tumor diameter was 2.4
m (median, 2.0 cm; range, 1.3–6.0 cm). The patients were first
eferred to the department of thoracic surgery. All patients were
etermined to be nonsurgical candidates by a surgeon because of
oor pulmonary function (predicted forced respiratory volume in
second  1000 mL, n  7), poor cardiac function (New York
lts
-up
)
Patient’s
outcome Cause of death
Recurrence at latest or
last follow-up
Alive Local
Death Coronary disease None
Alive None
Alive None
Death Cancer progression Local
Alive Local
Death Cancer progression Local, intrapulmonary
Alive None
Alive Local, lymph node,
intrapulmonary
Death Respiratory failure None
Alive None
Alive None
Alive None
Alive None
Alive None
Alive None
Alive None
Alive None
Alive None
Alive Local, intrapulmonaryresu
ollow
(mo
52
2
30.8
35.7
13.4
38.3
24.5
30.2
26.2
2.8
29.7
30.1
17.8
24.1
19.5
17.9
13.2
11.9
12.4
12.2and Cardiovascular Surgery ● Volume 134, Number 5 1307
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G
TSeart Association Class  III, n  3), poor performance status
status  2, n  4), or refusal to undergo surgery (n  6). The
ean forced respiratory volume in 1 second in the 7 patients
ith poor pulmonary function was 1.18 l (range, 0.97-1.45 l).
ll 20 patients underwent 23 RFA sessions, including 3 repeat
essions for the treatment of local progression after a previous
ession. None of these patients underwent adjuvant systemic
hemotherapy.
FA Techniques
he electrodes that were used in the 23 sessions included a
ultitined expandable electrode (LeVeen; Boston Scientific,
atick, Mass) with a 2-cm diameter array (n  9); a single
nternally cooled electrode (Cool-tip; Valleylab, Boulder, Colo)
ith a 1-cm (n  4), 2-cm (n  8), or 3-cm (n  1) noninsulated
ip; or an internally cooled cluster electrode (n  1) (Cool-tip).
ntil October 2003, only the internally cooled electrode was
vailable at our institution, and therefore this electrode was used in
ll procedures. Thereafter, the multitined expandable electrodes
ere made available. The procedure was always performed per-
utaneously with CT fluoroscopy. Intraprocedural pain was treated
y local anesthesia (n  20) or epidural anesthesia (n  3).
The patients were placed in the supine or prone positions
epending on the tumor location, and grounding pads were placed
n their thighs. After administration of anesthesia, the electrode
as introduced into the tumor and was connected to a generator. In
he case of the Valleylab device, radiofrequency energy was ap-
lied with an impedance control algorithm for 12 minutes during
nternal cooling of the electrode. Thereafter, the temperature was
easured at the electrode tip; if it had not reached 60°C, another
nergy application was added at the same site. When the Boston
cientific device was being used, the energy was applied until the
mpedance showed a rapid increase or an automatic shutoff oc-
urred at 15 minutes; this was repeated once at each site. The
blative margin was obtained by creating multiple overlapping
blation zones when using an electrode with an array diameter or
noninsulated tip length that was equal to or smaller than the
umor diameter.
ollow-up
he patients were followed up, whenever possible, at 1, 3, 6, 9, and
2 months and thereafter at 6-month intervals. As a result, all 20
atients were followed up at 1 month. A certain number of patients
hould have undergone subsequent periodic follow-up examina-
ions, that is, 18, 17, and 15 patients at 3 and 6, 9, and 12 months,
espectively. Of these, 17, 13, and 13 patients were followed up at
and 6, 9, and 12 months, respectively. Further, all of the 11
atients who should have undergone follow-up at 6-month inter-
als after 12 months were successfully followed up. At every
ollow-up, chest CT scan was performed to assess the RFA out-
omes. The images were obtained before and 30 and 90 seconds
fter the initiation of intravenous contrast administration at a rate
f 3 mL/s. For assessment of hematogenous metastasis, abdominal
T scanning was generally performed at 6-month intervals. A total
f 4 PET examinations were also performed for 3 patients; those
ere done at 2 months (n  1), 4 months (n  2), and 8 monthsn  1). When symptoms suggesting brain or bone metastasis w
308 The Journal of Thoracic and Cardiovascular Surgery ● Novere observed, we performed brain magnetic resonance imaging
r bone scintiscan, respectively.
Initial efficacy was assessed on CT images at 1 month; the
umor was considered to be treated if it was entirely covered by the
blation zone. As described in a previous study, in the first 3
onths, size of the ablated lesion usually exceeds that of the tumor
efore ablation even if the tumor is completely ablated; this is
ecause the zone of ablation includes the tumor and the ablated
argin of parenchyma to a certain extent.4 Hence, during this
eriod, the effectiveness of RFA can be determined not by com-
aring the tumor size but by assessing the contrast enhancement.
he tumor was considered to be completely treated when contrast
nhancement was not observed in the entire ablation zone or when
he ablation zone exhibited a peripheral rim of contrast enhance-
ent that was concentric, symmetric, and uniform with smooth
nner margins. Such an enhancement zone is considered to corre-
pond to reactive hyperemia, inflammation, or granulation at the
arginal parenchyma.4 After the first 3 months, the ablation zone
xhibits gradual involution over time when the tumor is com-
letely ablated.4 The appearance of irregular, scattered, nodular, or
ccentric foci in the ablation zones was considered to indicate the
ocal progression of the tumor.4 The focus generally exhibited
ontrast enhancement, thereby contrasting against the noncontrast-
nhanced necrotic tumor tissue. Local progression was also indi-
ated when the ablation zone was circumferentially enlarged; such
zone was generally accompanied by contrast enhancement.
Local control was defined as no evidence suggesting local
rogression by a first session. The local control rates and overall
nd cancer-specific survivals were estimated by the Kaplan–Meier
nalysis. Further, survivals were also estimated according to the
ancer stage (IA or IB).
esults
mong the 23 sessions, procedural complications included
neumothorax (n  13 [57%]) and pleural effusion (n  4
17%]). One patient with pneumothorax required chest tube
lacement; all other patients with pneumothoraces and pleu-
al effusion were treated conservatively. No hemorrhagic
vent requiring treatment was observed, and none of the
atients died as a result of this procedure. The median
ospital stay was 4 days (range, 2–17 days). The follow-up
esults are summarized in Table 1. The median follow-up
eriod was 21.8 months (range, 2–52 months). In all the
atients, the tumor was considered to be treated with initial
fficacy on CT images at 1 month. Local progression was
bserved in 7 (35%) patients at 4.4 to 38.3 months (mean,
3.6 months; median, 9.0 months) after the first session. In
of these patients, biopsy was performed to confirm the
ocal progression; the remaining patients did not undergo
iopsy because local progression was obvious on CT im-
ges. Three PET examinations at 2 or 4 months showed
ositive results, which were in contrast to the results on CT
mages at the same period; the tumors were then monitored
y CT and have not shown local progression. One PET at 8
onths showed a negative result, which was in accordance
ith the result on CT; the tumor was then monitored by CT
ember 2007
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TSnd has not shown local progression. The local control rates
ere 72% at 1 year, 63% at 2 years, and 63% at 3 years. Of
he 7 patients with local progression, 2 were treated with a
otal of 3 repeat sessions. Thereafter, local progression was
ot observed in 1 of the 2 patients. The other 5 patients with
ocal progression were treated with XRT (n  1), systemic
hemotherapy (n  3) because of coexistent lymphatic
nd/or hematogenous metastasis, or are awaiting repeat
FA (n  1).
Of the 20 patients, 4 died at the time of study. Of these,
died of cancer progression and the remaining 2 died of
ther causes; 16 patients survived. Of the 16 patients, 12
ere free of recurrence and 4 showed recurrences some-
here. The mean survival time was 42 months; the median
urvival was not reached. The overall survival and cancer-
pecific survivals (95% confidence intervals) were 90%
77%–100%) and 100% (100%–100%) at 1 year, 84%
66%–100%) and 93% (79%–100%) at 2 years, and 74%
51%–97%) and 83% (60%–100%) at 3 years, respectively
Figure 1). The survivals (95% confidence intervals) with
egard to stages IA and IB cancer were 93% (79%–100%)
nd 83% (54%–100%) at 1 year, 93% (79%–100%) and
7% (29%–100%) at 2 years, and 80% (53%–100%) and
navailable at 3 years, respectively (Figure 2).
iscussion
FA appears to be a promising treatment modality for
epatocellular and renal cell carcinoma in terms of local
ontrol and patient survival. The local recurrence rate was
4.9% (352/2369) for hepatocellular carcinoma and 0% to
9% for renal cell carcinoma.5-7 However, it should be
oted that NSCLC exhibits a different biologic behavior
rom those cancers. NSCLC frequently shows microscopic
igure 1. The overall survival and cancer-specific survivals were
0% and 100% at 1 year, 84% and 93% at 2 years, and 74% and 83%
t 3 years, respectively.nvasion of the lymphatic vessels and finally metastasizes to d
The Journal of Thoraciche regional lymph nodes. In fact, pathologic examinations
emonstrated that approximately 20% of even small (2
m in diameter) NSCLCs showed lymph node metastasis.8
ecause RFA represents only a local therapy, a higher risk
f locoregional recurrence and thereby poorer survival is
xpected as compared with the use of lobectomy accompa-
ied by systematic lymph node sampling or dissection. In
he present study, therefore, application of this therapy was
imited to the patients who had inoperable disease or who
efused surgery.
An international survey reported that RFA of lung tumors is
safe procedure with an extremely low mortality rate (0.4%).9
he most common complication is pneumothorax, but the
ajority of patients are treated conservatively.9,10 Although
id- to long-term local control remains poorly understood,
ost of the previous studies with a mean follow-up of 1
ear or more have shown a primary local control rate of
pproximately 60% to 70%,11-14 which is applicable in our
tudy. The local control outcomes of lung cancers seem
nferior to those of hepatocellular and renal cell carcinoma,
hich may be explained by the following reasons: micro-
copic tumor extension and the difficulty in achieving an
dequate treatment margin owing to the severely limited
lectrical and thermal conductivity of the air-containing
ung tissues. Compared with the outcomes after surgical
esection of stage I NSCLC, the local progression rate of
5% in our study is much higher. One of the important
imitations of RFA is the difficulty of realizing the precise
xtent of treatment zone during the procedure; this likely
ontributes to the relatively high local progression rate.
ppearance of ground-glass opacity surrounding treated
umors might aid in recognizing the extent of ablation zone,
ut it does not indicate the exact extent of coagulation
ecrosis.15
Although the literature contains only limited survival
igure 2. The survivals with regard to stages IA and IB cancer
ere 93% and 83% at 1 year, 93% and 67% at 2 years, and 80% and
navailable at 3 years, respectively.ata after RFA of NSCLC, Ambrogi and colleagues13
and Cardiovascular Surgery ● Volume 134, Number 5 1309
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G
TSeported the outcomes in 40 patients with NSCLC (unknown
taging): a mean survival time of 19 months and survivals of
pproximately 70% at 1 year, approximately 45% at 2 years,
nd 30% at 3 years. Thanos and associates16 reported sur-
ivals of approximately 80% at 1 year, approximately 65%
t 2 years, and approximately 10% at 3 years in 14 patients
ith stage II-IV cancer. Fernando and colleagues12 reported
survival of approximately 80% at 2 years in 18 patients
ncluding 9 patients with stage I cancer. Simon and col-
eagues17 reported survivals of 78%, 57%, 36%, and 27% at
, 2, 3, and 5 years, respectively, in 75 patients with stage
NSCLC (stage IA, n  56; stage IB, n  19). Although
he survival data in our study appear to be better than the
forementioned data, a relatively high rate of including the
atients who were operable but refused surgery or those
ho had lesions showing pure ground-glass opacity might
ave contributed to this better survival. As expected, the
urvival in patients with stage IA cancer seemed better than
hat of patients with stage IB cancer in our study, but a
eaningful comparison analysis was, regrettably, not al-
owed because of the small study population.
Nonsurgical candidates with NSCLC are generally
reated with conventional XRT. In a study on 71 patients
ith node-negative NSCLC who underwent XRT, overall
nd disease-specific survivals were 19% and 44% at 3 years,
espectively.18 Another study reported a local recurrence
ate of 53% and the median survival of 20 months for 60
atients with stage I or II cancer who underwent XRT.19
eta-analysis of stage I NSCLC treated by conventional
RT revealed mean overall and cause-specific survivals at
years of 34% and 39%, respectively.20 Stereotactic radio-
herapy, a novel radiation therapy, shows favorable local
ontrol and survivals and may rival RFA. For stage I cancer,
he local recurrence rate ranged from 2% to 20% at a
edian follow-up period of longer than 1 year21-24; surviv-
ls were 80% or more at 1 year,22-24 58% to 75% at 2
ears,22-24 and 55% at 3 years.22 In future, it would be
nteresting to compare RFA with XRT including stereotac-
ic radiotherapy in a randomized controlled study.
The challenging issue after RFA may be the radiologic
valuation of local efficacy. Unlike surgical resection, the
blated tumor remains in situ and thereby assessment of
ocal efficacy is more difficult. The tissue surrounding a
umor that undergoes coagulation necrosis may increase the
ize of the imaging abnormality immediately after RFA.
his phenomenon may cause a tumor that has been com-
letely ablated to appear to have grown. On subsequent
ollow-up, lesions visualized on CT imaging frequently do
ot undergo significant shrinkage, even if no viable tissue is
resent. Therefore, tumor size after RFA does not exactly
orrelate with tumor viability, and thus we evaluated local
fficacy with the aid of contrast enhancement. However, it
s true that contrast enhancement of local progression was r
310 The Journal of Thoracic and Cardiovascular Surgery ● Novot always sufficiently clear to make judgments because
SCLC is originally not so hypervascular. PET might be
ore useful for evaluation; however, its role has not yet
een determined. As well as the potential, PET might have
limitation in that inflammation induced by RFA may result
n false positive results, especially in the early period after
FA. Regarding biopsy, we suggest that it is not a suitable
outine follow-up modality because it is invasive and in-
olves risks such as pneumothorax, hemothorax, and sys-
emic air embolism. Further, considering that the treated
umor contains necrotic tissue, even if it is not completely
reated, a small specimen obtained by biopsy may result in
high false negative rate. Thus, we performed it only in
elected cases.
The restricted ablation volume is clearly an important
imitation of RFA. Lung tumors larger than 3 cm are at a
igher risk of local recurrence than smaller tumors.6,9
upuy and coworkers25 performed RFA followed by con-
entional XRT in 24 patients with stage I cancer (mean size,
.4 cm). The local progression rate of 8.3% (2/24) at the
ean follow-up of 26.7 months appeared quite promising
iven the large tumor sizes and longer follow-up in their
tudy. Such favorable outcomes encourage combining XRT
nd RFA, especially for treating larger tumors. Combination
f RFA with chemotherapy may be another option to im-
rove the outcomes. In an animal experiment, RFA fol-
owed by intravenous chemotherapy provided larger coag-
lation than RFA alone.26 Systemic chemotherapy may also
acilitate treatment of microscopic metastasis that possibly
ccurs in clinical stage I cancer.
Rapid development of technology will improve the cur-
ent RFA system to provide more predictable and consistent
oagulation and thereby minimize local progression. In an-
mal studies, successful enlarged coagulation necrosis was
btained by various attempts, including modulation of con-
uctivity,27 blood perfusion,28 and ventilation.29 Thus, ap-
lication of these techniques to the clinical setting could
ossibly improve local control. Our outcomes might be
mpaired owing to the use of internally cooled electrodes in
he early part of our study because internally cooled elec-
rodes exhibited inferior local control as compared with
ultitined expandable electrodes.14 Anyhow, RFA has just
merged in the treatment of lung cancer, and much work
ill be done to enhance its efficacy. Notable advantages of
FA include the low invasiveness, preservation of pulmo-
ary function,13 the freedom to perform the procedure re-
ardless of any previous therapy, and the availability to
epeat procedures whenever required. Therefore, despite the
nherent limitation of local therapy in the treatment of
SCLC, RFA may have the potential to play an important
ole in the treatment of localized cancer.
Our study had several limitations. This is a retrospectiveeview, possibly with selection biases. The biases may make
ember 2007
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G
TSt difficult to compare our data with the data obtained in
ther studies and to draw a conclusion regarding the role of
FA in the treatment of NSCLC. Treatment parameters
uch as ablation device and algorithm were heterogeneous.
ET was not used for radiologic assessment of the disease
n most patients. Over the past years, the use of PET has
ignificantly improved nonsurgical staging.30 The limited
se of PET and the unavailability of mediastinoscopy for
reprocedural cancer evaluation might affect the reliability
f cancer staging in our study. Inasmuch as the rationale for
pplication of local therapy is based on localization of the
isease, candidates for RFA should be appropriately se-
ected by use of the most reliable modality. The survivals of
atients in the present study were promising, but the study
as carried out on a small study population. Currently, a
rospective study on RFA of stage I NSCLC with the use of
niform ablation parameters, a combination of XRT and
hemotherapy for selected cancers, and PET scan for radio-
ogic assessment is in progress at our institution.
In conclusion, treating clinical stage I NSCLC with one
r more RFA sessions provided promising outcomes in
erms of survival. However, considering the relatively high
ocal progression rate, RFA should be considered only for
onsurgical candidates.
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